Adamis Pharmaceuticals Corporation (ADMP) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Adamis Pharmaceuticals Corporation (ADMP) Healthcare & Pipeline Overview

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical firm developing and commercializing products across allergy, opioid overdose, respiratory, and inflammatory disease therapeutic areas in the U.S. Its portfolio features SYMJEPI epinephrine pre-filled syringes for anaphylaxis, dry powder inhalers for asthma, and naloxone injections, addressing critical unmet medical needs within the pharmaceutical market.

What Is the Investment Thesis for ADMP?

Adamis Pharmaceuticals Corporation presents an investment profile centered on its specialized product development and commercialization efforts within critical therapeutic areas, notably allergy and opioid overdose. The company's lead commercial product, SYMJEPI epinephrine pre-filled syringe, addresses the ongoing need for emergency anaphylaxis treatment, a market with consistent demand. Additionally, its naloxone injection product targets the persistent opioid overdose crisis, representing a significant public health imperative. The pipeline further includes dry powder inhalers for asthma and novel candidates like APC400 for radiation dermatitis and APC410 for various respiratory diseases, indicating potential for portfolio expansion. However, the company operates with a market capitalization of $7.25M and faces significant financial challenges, evidenced by a profit margin of -556.7% and a gross margin of -60.9%. This reflects the typical risks associated with smaller pharmaceutical companies, including reliance on a limited product line and intense competition from established players. Future value creation is highly dependent on the successful clinical development, regulatory approval, and commercialization of its pipeline assets, particularly achieving sustainable profitability and expanding its market presence for existing products. Investors should closely monitor the company's ability to navigate these financial hurdles and effectively execute its product development and commercialization strategies to realize potential growth.

Based on FMP financials and quantitative analysis

ADMP Key Highlights

• Market Capitalization: $0.01 billion, indicating a micro-cap company operating within the specialty biopharmaceutical sector.
• Profit Margin: -556.7%, reflecting significant net losses relative to revenue, a common characteristic for development-stage or early commercial-stage biopharmaceutical firms.
• Gross Margin: -60.9%, suggesting that the cost of goods sold currently exceeds net sales, highlighting commercialization challenges or high manufacturing costs relative to pricing.
• Beta: 1.28, indicating that the stock's price tends to be more volatile than the overall market, aligning with the higher risk profile often associated with smaller pharmaceutical companies.
• Employee Count: 11 employees, underscoring a lean operational structure for a company engaged in drug development and commercialization across multiple therapeutic areas.

Who Are ADMP's Competitors?

ADMP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ADMP's Key Strengths?

• Commercialized product (SYMJEPI) addressing a critical emergency medical need.
• Diversified pipeline targeting multiple therapeutic areas including allergy, opioid overdose, and respiratory diseases.
• Strategic focus on specialized drug delivery methods like pre-filled syringes and dry powder inhalers.
• Engagement in both human and veterinary pharmaceutical markets.

What Are ADMP's Weaknesses?

• Small market capitalization ($0.01B) and limited financial resources compared to larger competitors.
• Significant negative profit (-556.7%) and gross (-60.9%) margins, indicating profitability challenges.
• Reliance on a limited number of commercialized products for current revenue.
• High beta (1.28) suggests higher stock price volatility.

What Could Drive ADMP Stock Higher?

• Potential regulatory milestones or approvals for pipeline candidates like APC400 or APC410, which could significantly de-risk development and open new market opportunities.
• Continued commercialization efforts and market penetration for SYMJEPI epinephrine pre-filled syringes, driving increased sales volume and market share in the anaphylaxis treatment segment.
• Advancement of dry powder inhaler products through clinical trials for asthma, potentially leading to positive data readouts and subsequent regulatory submissions.
• Expansion of distribution and adoption of the naloxone injection product, addressing the critical and persistent demand for opioid overdose reversal agents.
• Formation of strategic partnerships or licensing agreements for pipeline assets, potentially providing non-dilutive funding and accelerating development or commercialization.

What Are the Key Risks for ADMP?

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Significant financial losses, as evidenced by a -556.7% profit margin and -60.9% gross margin, raising concerns about long-term financial sustainability and the need for future capital raises.
• High reliance on a limited product line, particularly SYMJEPI, meaning that any market challenges or increased competition for this product could severely impact revenue.
• Intense competition from larger, more established pharmaceutical companies with greater financial and marketing resources in all therapeutic areas Adamis targets.
• Clinical trial failures or unexpected adverse events for pipeline candidates (APC400, APC410, dry powder inhalers), which could lead to significant delays or abandonment of development programs.
• Regulatory hurdles and the inherent uncertainties of the drug approval process, which can delay or prevent products from reaching the market.

What Are the Growth Opportunities for ADMP?

• Growth opportunity 1: Expansion of SYMJEPI Market Penetration: Adamis Pharmaceuticals' SYMJEPI epinephrine pre-filled syringe addresses the critical need for emergency treatment of acute allergic reactions, including anaphylaxis. The global anaphylaxis treatment market is projected to continue growing, driven by increasing allergy prevalence and demand for convenient, easy-to-use auto-injectors. By focusing on expanding market penetration and securing broader formulary access for SYMJEPI, Adamis can capitalize on this ongoing demand. The product's pre-filled syringe design offers a competitive advantage in terms of ease of use and potentially reduced administration errors compared to traditional vial-and-syringe systems, positioning it for increased adoption among patients and healthcare providers over the next 3-5 years.
• Growth opportunity 2: Development of Dry Powder Inhalers for Asthma: The company's pipeline includes dry powder inhaler products for the treatment of asthma, a chronic respiratory condition affecting millions globally. The global asthma and COPD market is substantial, with a continuous need for effective and patient-friendly inhalation therapies. Successful development and regulatory approval of these inhalers would allow Adamis to enter a large and established market segment. This opportunity involves leveraging advancements in drug delivery technology to offer improved therapeutic options, potentially capturing a share of the market by providing differentiated products within the next 5-7 years, contingent on clinical trial success and regulatory milestones.
• Growth opportunity 3: Commercialization of Naloxone Injection for Opioid Overdose: Adamis' naloxone injection product targets the critical and persistent public health crisis of opioid overdose. The demand for naloxone has significantly increased due to the ongoing opioid epidemic, making it a vital emergency medication. Successful commercialization and broader distribution of its naloxone injection can tap into this urgent market need. This represents a significant growth opportunity by contributing to public health efforts while establishing a reliable revenue stream. The market for opioid overdose reversal agents is expected to remain robust, offering a sustained opportunity over the next 5-10 years as the crisis continues to be addressed.
• Growth opportunity 4: Advancement of APC400 for Radiation Dermatitis: The company is developing APC400, a tempol gel designed to reduce radiation dermatitis in cancer patients. Radiation dermatitis is a common and often debilitating side effect of radiation therapy, representing a significant unmet medical need in oncology supportive care. Successful clinical development and regulatory approval of APC400 would allow Adamis to enter a specialized market focused on improving the quality of life for cancer patients. This niche market, while smaller than broader therapeutic areas, offers potential for strong adoption due to the lack of highly effective current treatments, with potential market entry within 5-8 years, pending clinical trial outcomes.
• Growth opportunity 5: Development of APC410 for Broad Respiratory Diseases: APC410 is a pipeline candidate targeting a range of respiratory diseases, including asthma, RSV, influenza, and COVID-19. This broad therapeutic scope positions Adamis to address multiple prevalent viral and chronic respiratory conditions. The global market for respiratory disease treatments is vast and continuously evolving, particularly with the emergence of new viral threats. Successful development and commercialization of APC410 could provide a significant revenue stream by offering innovative solutions for both chronic and acute respiratory conditions, potentially within the next 7-10 years, depending on the specific indications pursued and clinical success.

What Opportunities Does ADMP Have?

• Expansion of SYMJEPI market share through increased adoption and distribution.
• Successful clinical development and commercialization of pipeline assets like APC400 and APC410.
• Addressing the ongoing public health crisis of opioid overdose with its naloxone injection.
• Potential for strategic partnerships or licensing agreements to accelerate product development and market access.

What Threats Does ADMP Face?

• Intense competition from established pharmaceutical companies with greater resources.
• Regulatory hurdles and potential delays in drug approval processes.
• Clinical trial failures or unfavorable efficacy/safety profiles for pipeline candidates.
• Market acceptance and reimbursement challenges for new products.
• Patent expirations or challenges to intellectual property.

What Are ADMP's Competitive Advantages?

• Proprietary product formulations and drug delivery systems, such as the SYMJEPI pre-filled syringe.
• Specialization in niche therapeutic areas with ongoing unmet medical needs, like emergency allergy and opioid overdose.
• Intellectual property protection (patents) for its pipeline candidates like APC400 and APC410.
• Regulatory approvals for commercialized products, creating barriers to entry for new competitors.

What Does ADMP Do?

Adamis Pharmaceuticals Corporation, founded in 2006 and headquartered in San Diego, California, operates as a specialty biopharmaceutical company dedicated to the development and commercialization of a diverse range of therapeutic products within the United States. The company strategically targets several critical therapeutic areas, including allergy, opioid overdose, respiratory, and inflammatory diseases. A cornerstone of its product portfolio comprises SYMJEPI epinephrine pre-filled syringe injectable products, specifically designed for the emergency treatment of acute allergic reactions, notably anaphylaxis. This product addresses a vital need in emergency medicine, offering a pre-filled, ready-to-use solution. Beyond allergy, Adamis is actively engaged in the respiratory disease space, developing dry powder inhaler products aimed at treating asthma, a chronic condition affecting millions globally. The company also plays a role in public health initiatives through its naloxone injection product, intended for the emergency treatment of opioid overdose, a significant and ongoing crisis. Expanding its pipeline, Adamis is advancing APC400, a tempol gel formulation under development for its potential use in reducing radiation dermatitis in cancer patients undergoing treatment, addressing a common and debilitating side effect of oncology therapies. Furthermore, APC410 represents another key pipeline asset, targeting a broader spectrum of respiratory diseases, including asthma, respiratory syncytial virus (RSV), influenza, and COVID-19, indicating a strategic focus on prevalent respiratory conditions. In addition to its proprietary product candidates, Adamis Pharmaceuticals Corporation also engages in providing a range of other pharmaceutical products, which include corticosteroids, hormone replacement therapies, hospital outsourcing products, and various injectables. The company also extends its reach into the veterinary pharmaceutical market, offering products tailored for animal health. With a lean team of 11 employees, Adamis navigates the competitive biopharmaceutical landscape by focusing on specialized product development and commercialization.

What Products and Services Does ADMP Offer?

• Develops and commercializes SYMJEPI epinephrine pre-filled syringes for severe allergic reactions (anaphylaxis).
• Develops dry powder inhaler products for the treatment of asthma.
• Develops naloxone injection for the emergency treatment of opioid overdose.
• Advances APC400, a tempol gel, for reducing radiation dermatitis in cancer patients.
• Develops APC410 for various respiratory diseases, including asthma, RSV, influenza, and COVID-19.
• Provides corticosteroids, hormone replacement therapies, hospital outsourcing products, and injectables.
• Offers veterinary pharmaceutical products for animals.

How Does ADMP Make Money?

• Generates revenue through the sale of commercialized pharmaceutical products like SYMJEPI.
• Aims to generate future revenue from successful development, regulatory approval, and commercialization of pipeline drug candidates.
• Potentially earns revenue through licensing agreements or partnerships for its drug candidates.
• Provides specialized pharmaceutical products for hospital outsourcing and veterinary markets.

What Industry Does ADMP Operate In?

Adamis Pharmaceuticals Corporation operates within the highly competitive and regulated Drug Manufacturers - Specialty & Generic industry, a segment of the broader Healthcare sector. This industry is characterized by significant R&D investments, lengthy regulatory approval processes, and intense competition from both large pharmaceutical conglomerates and smaller biotech firms. Market trends include a growing demand for specialized treatments, an increasing focus on addressing public health crises like the opioid epidemic, and advancements in drug delivery systems such as pre-filled syringes and dry powder inhalers. Adamis positions itself by developing and commercializing products in niche yet critical therapeutic areas like emergency allergy treatment (SYMJEPI) and opioid overdose reversal (naloxone). While these areas represent ongoing market needs, the company faces established competitors with greater financial resources and broader distribution networks. Its success hinges on differentiating its products, achieving market penetration, and effectively managing its lean operational structure against industry giants.

Who Are ADMP's Key Customers?

• Patients requiring emergency treatment for anaphylaxis (via prescriptions for SYMJEPI).
• Healthcare providers and emergency medical services (for SYMJEPI and naloxone).
• Hospitals and healthcare facilities (for outsourcing products, corticosteroids, hormone replacement therapies, injectables).
• Patients suffering from asthma and other respiratory conditions (future market for inhalers and APC410).
• Cancer patients undergoing radiation therapy (future market for APC400).
• Veterinary clinics and animal owners (for veterinary pharmaceutical products).

Company Profile

Adamis Pharmaceuticals Corporation operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Ebrahim Versi. ADMP has traded publicly since 1995.

ADMP Valuation & Market Position

With a $7.25M market cap, Adamis Pharmaceuticals Corporation sits in the micro-cap segment of the market. Relative to its peer group, ADMP's quantitative score of 61/100 is roughly in line with the peer average of 62/100.

F-Score 3/9Financial Health

Adamis Pharmaceuticals Corporation's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

ADMP Financials

ADMP Latest News

ADMP Analyst Consensus

ADMP MoonshotScore

ADMP Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources